Quotes 5-day view End-of-day quote Shenzhen Stock Exchange
08/10/2022
08/11/2022
08/12/2022
08/15/2022
08/16/2022
Date
44.74
44.39
43.08
42.4
41.95
Last
19145400
15630400
14905270
20689950
9802856
Volume
+1.80%
-0.78%
-2.95%
-1.58%
-1.06%
Change
Estimated financial data (e) CNY USD
Sales 2022
38 384 M
5 655 M
5 655 M
Net income 2022
2 810 M
414 M
414 M
Net cash position 2022
3 143 M
463 M
463 M
P/E ratio 2022
26,1x
Yield 2022
0,75%
Sales 2023
42 066 M
6 197 M
6 197 M
Net income 2023
3 395 M
500 M
500 M
Net cash position 2023
4 702 M
693 M
693 M
P/E ratio 2023
21,6x
Yield 2023
0,93%
Capitalization
73 405 M
10 814 M
10 814 M
EV / Sales 2022
1,83x
EV / Sales 2023
1,63x
Nbr of Employees
12 427
Free-Float
41,8%
Huadong Medicine Co., Ltd. specializes in the development, manufacture and marketing of medical products and vaccines. The products are intended primarily for the treatment of tumors, immune disorders, endocrine disorders, orthopedic and traumatological disorders, digestive system diseases and viral diseases.
Ratings of Huadong Medicine Co., Ltd
All news about HUADONG MEDICINE CO., LTD
08/09 Huadong Medicine Buys 60% of Nanomaterials Maker Wuhu Huaren For $57 Million MT
08/09 Huadong Medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 202.. CI
06/02 Huadong Medicine Co., Ltd Approves Board Appointments CI
06/02 Huadong Medicine Co., Ltd Approves Cash Dividend on A Shares for the Year 2021, Payable.. CI
04/28 Huadong Medicine's 2021 Profit Plunges 18% Despite Higher Sales; Shares Jump 5% MT
04/28 Huadong Medicine Co., Ltd Proposes Final Cash Dividend for the Year 2021 CI
04/27 Huadong Medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31.. CI
04/27 Huadong Medicine Co., Ltd Reports Earnings Results for the Full Year Ended December 31,.. CI
04/27 Ashvattha Therapeutics, Inc. announced that it has received $69 million in funding from.. CI
02/28 Huadong Medicine Buys 35% Stake in German Cancer Drug Firm Heidelberg for $117.5 Millio.. MT
02/28 Heidelberg Pharma Grants Up to $930 Million Drug Development License to China's Huadong.. MT
02/27 Huadong Medicine Co., Ltd agreed to acquire 9% stake in Heidelberg Pharma AG from dievi.. CI
02/23 Huadong Medicine Bags Exclusive Rights for US-Based Kiniksa's Autoimmune Drugs MT
02/09 AKSO and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize.. BU
2021 HUADONG MEDICINE CO., LTD : 3rd quarter reportCO
News in other languages on HUADONG MEDICINE CO., LTD
Chart HUADONG MEDICINE CO., LTD
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends HUADONG MEDICINE CO., LTD
Short Term Mid-Term Long Term Trends Bearish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
9
Last Close Price
41,95 CNY
Average target price
45,05 CNY
Spread / Average Target
7,39%
Please enable JavaScript in your browser's settings to use dynamic charts.